Journalism in the Public Interest


April 17, 2013 Archives

Forever Blowing Bubbles

Double Dose: In Second Case of Flawed Drug Research, FDA Response Was Slow and Secretive

This week ProPublica reported that the Food and Drug Administration found "egregious" research violations at a major laboratory but didn't pull any affected drugs from the market and, years later, hasn't finished its review. Turns out that wasn't an anomaly.